Key Points
- Stryker insider Dylan Bram Crotty sold 441 shares at an average price of $328.61, generating $144,917.01 and reducing his direct ownership by 6.74% to 6,102 shares.
- Stryker reported quarterly EPS of $3.69, beating estimates of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company also declared a quarterly dividend of $0.88 per share, representing a 1.1% yield.
- Analysts maintain a consensus “Moderate Buy” rating with a $386.28 target price, although recent ratings included both price-target reductions and a downgrade to “peer perform.”
Stryker Corporation (NYSE:SYK - Get Free Report) insider Dylan Bram Crotty sold 441 shares of the firm's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider directly owned 6,102 shares of the company's stock, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Stryker Price Performance
Shares of SYK opened at $330.08 on Thursday. The business's 50-day moving average is $328.37 and its two-hundred day moving average is $331.72. The company has a market capitalization of $126.61 billion, a P/E ratio of 34.21, a P/E/G ratio of 2.11 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86.
Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the prior year, the firm posted $3.13 EPS. The business's quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts predict that Stryker Corporation will post 15.02 earnings per share for the current year.
Stryker Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's payout ratio is presently 36.48%.
Institutional Trading of Stryker
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SYK. VanderPol Investments L.L.C. grew its position in Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock valued at $732,000 after buying an additional 28 shares during the period. Rossby Financial LCC raised its position in Stryker by 6.6% in the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock worth $159,000 after acquiring an additional 28 shares during the period. KCM Investment Advisors LLC boosted its stake in Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock valued at $653,000 after acquiring an additional 28 shares during the last quarter. Tcfg Wealth Management LLC grew its position in shares of Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock valued at $403,000 after acquiring an additional 29 shares during the period. Finally, Sompo Asset Management Co. Ltd. grew its position in shares of Stryker by 1.3% during the 2nd quarter. Sompo Asset Management Co. Ltd. now owns 2,390 shares of the medical technology company's stock valued at $946,000 after acquiring an additional 30 shares during the period. Hedge funds and other institutional investors own 77.09% of the company's stock.
Analyst Upgrades and Downgrades
SYK has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a report on Friday, May 1st. Barclays dropped their price objective on shares of Stryker from $469.00 to $394.00 and set an "overweight" rating for the company in a research note on Monday, May 4th. UBS Group assumed coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a "buy" rating and a $400.00 price objective for the company. BTIG Research decreased their target price on shares of Stryker from $371.00 to $358.00 and set a "buy" rating on the stock in a research note on Friday, July 31st. Finally, Wolfe Research lowered Stryker from an "outperform" rating to a "peer perform" rating in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and a consensus price target of $386.28.
Read Our Latest Stock Report on Stryker
Stryker Company Profile
(
Get Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
